Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.
Perm J
; 26(1): 123-131, 2021 10 29.
Article
in English
| MEDLINE | ID: covidwho-1863290
ABSTRACT
INTRODUCTION:
Relapsing COVID-19 infections have been reported, but their etiology and severity are still unknown. In addition, there have been no cases in the literature that associate relapsing infection with immunosuppression, either from a disease course or medications. CASE PRESENTATION This case series illustrates two patients who developed a relapsed infection, likely from recent rituximab infusions. In addition, both cases depicted a severe form of infection than the initial one. Laboratory investigations revealed these patients were unable to produce COVID-19 antibodies, even though one of the patients received convalescent plasma.CONCLUSION:
Clinicians should be aware of the possibility of relapsing COVID-19, especially in immunosuppressed patients. Because rituximab induces B-cell depletion, it can also decrease the effectiveness of the COVID-19 vaccine. Therefore, these patients should receive the vaccine before their scheduled rituximab infusion.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Rituximab
/
COVID-19
/
Immunosuppressive Agents
Type of study:
Case report
/
Diagnostic study
/
Etiology study
/
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Perm J
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS